当前位置： SCI文献检索 > SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY期刊下所有文献 > Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.

Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.

Abstract：

OBJECTIVE:Interferon-free therapy for hepatitis C virus (HCV) infection is costly, and therefore patients with advanced fibrosis are prioritized. Although coupled with considerable side effects, a large proportion of genotype 2/3 infected patients achieve a sustained virological response (SVR) following interferon-based therapy. The present study evaluates experimental clinical trial and verifying real-life data with the aim of identifying patients with a high likelihood of favorable outcome following short interferon-based treatment. MATERIAL AND METHODS:The impact of established response predictors, e.g. age, ITPA and IL28B genetic variants, IP-10, liver histopathology and early viral kinetics on outcome was evaluated among HCV genotype 2/3 infected patients enrolled in the NORDynamIC trial. Similarly outcome was evaluated among Finnish and Swedish real-life genotype 2/3 infected patients treated for 12-16 weeks in accordance with national guidelines. RESULTS:In the NORDynamIC trial, age < 40 years or achieving HCV RNA < 1000 IU/mL day 7 were highly predictive of favorable outcome following 12 weeks therapy. Among 255 Finnish real-life patients below the age of 40 years treated for 12 weeks with interferon and ribavirin, 87% of HCV genotype 2 and 79% of genotype 3 infected patients achieved SVR, and among 117 Swedish real-life patients treated for 12-16 weeks, 97% of HCV genotype 2 and 94% of genotype 3 infected achieved SVR. CONCLUSIONS:Short interferon-based therapy offers a high likelihood of achieving SVR for selected HCV genotype 2/3 infected patients, and is an acceptable option given that a thorough discussion of the side effects is provided prior to initiation.

journal_name

Scand J Gastroenterol

journal_title

Scandinavian journal of gastroenterology

authors

Waldenström J,Färkkilä M,Rembeck K,Norkrans G,Langeland N,Mørch K,Pedersen C,Rauning Buhl M,Nieminen U,Nuutinen H,Alsiö Å,Holmström L,Jungnelius R,Lund K,Rubensson A,Torell E,Westin J,Lagging M

doi

10.3109/00365521.2015.1087588

subject

Has Abstract

pub_date

2016-03-01 00:00:00

pages

337-43

issue

eissn

0036-5521

issn

1502-7708

journal_volume

pub_type

杂志文章,多中心研究,随机对照试验

在线工具

Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.